Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. - Wikidata - wikimedia - TriplyDB

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.

http://www.wikidata.org/entity/Q43265482

about

Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders NMDA receptors and fear extinction: implications for cognitive behavioral therapy D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning Pharmacological treatment of PTSD - established and new approaches Behavioral and neurobiological mechanisms of extinction in Pavlovian and instrumental learning Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Interoception and learning: import to understanding and treating diseases and psychopathologies Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective Emerging drugs for the treatment of anxiety D-cycloserine effects on extinction of conditioned responses to drug-related cues Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy.An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders Chronic antidepressant treatment impairs the acquisition of fear extinction.Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder Pharmacological enhancement of fear reduction: preclinical models.Glutamate receptors in extinction and extinction-based therapies for psychiatric illness A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis.Novel approaches in treatment of pediatric anxiety.Combining d-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke.D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?A novel treatment for tinnitus and tinnitus-related cognitive difficulties using computer-based cognitive training and D-cycloserine Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo.D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia.Pharmacological enhancement of drug cue extinction learning: translational challenges.Cognitive enhancers for anxiety disorders.Cognitive enhancers for facilitating drug cue extinction: insights from animal models.

P2860

Q22305514-90B1113F-3DFE-4003-B2C3-999409158541 Q24187995-B6065D99-94C1-480D-8477-B5D1CCA59226 Q24604822-E76C4739-78D0-40F6-8E0D-DC2963359537 Q24626679-773716EF-8AE3-4EEC-A255-836BE4317EA8 Q24633256-BB1DC6C2-2BEC-4E40-8F89-5DB765D1BA81 Q27001253-E2CD2679-02C8-4B9A-9210-8712CF4E251A Q27006437-062BCC80-9CC9-4145-86AF-38C478155720 Q27009995-A23CC949-F1DD-4ACA-A740-62FC318F005B Q27013751-28DAA779-259B-4FD9-B661-84B09D0DA581 Q27026213-064D159A-8CC2-49E6-8150-13165934DDD4 Q27026313-61E24D3B-4650-4B96-97A7-7C73E5A91A3E Q28083141-3804623C-541D-44A2-8C3A-725CB79A0396 Q28266461-BDF2BB3A-BCE1-4AD1-876F-70DBE7CD47CD Q30358603-FF788E39-B3CC-415E-B7C0-FA0CEA94611C Q30375098-5D62D39A-5301-47D3-8D2C-7A0832DE24E2 Q30380118-31A53578-671D-48F5-B343-2621EC6B3C5B Q30426498-2A823671-3D5A-46DE-9A94-ACF840EB1DC0 Q30437449-56AB489B-2034-48D0-927F-875C566DC4CF Q30459672-0A64A4B4-A624-4CAA-8A65-C2249C4E92F7 Q30462825-224AECB2-C208-40DF-A969-1EB5EB202221 Q30477927-D34FD038-2BCE-4F2C-A711-36339E1BC5B5 Q30498105-4B7D945D-4673-449D-8C8B-EAEF551CFAB9 Q30585383-7657C2A0-34DC-4F1A-88A3-EA3FBE1EFE03 Q31171981-69130B67-56E6-4520-9388-6A80ACA412C4 Q33598320-C20C480F-3D8B-4BA0-8E46-3FFC4661494F Q33708292-F31944C0-FB2E-4578-AFF4-461AA3148A03 Q33760626-8D32A135-1B54-467E-BC9A-C5F8EEB2E0A8 Q33835384-83786073-43EA-497C-BF6F-26C334C76D5C Q33912531-86504D83-F86E-46D4-A490-3853A3FBD50F Q33966168-C6467A87-D575-416F-A60C-E288A825EAB3 Q34017493-4BB9A8E3-0FDC-4398-B2DE-4CE7B5FE8091 Q34286452-FE84FE1F-422F-49BB-A898-4C84A4BC5218 Q34350942-0047F6C8-4493-4386-A9BB-C675657DCB11 Q34381226-30B3E52D-0236-42BA-9A7F-780001E7D122 Q34500045-CE28BE4E-E5AE-411B-AEBE-1D4D9734B51F Q34562562-F5C69798-E257-438A-8B31-BD3FBA306E87 Q34614646-5A057A34-3CD1-41CC-A7CD-C55F28B9F088 Q34721646-E000B36A-9F04-4AD0-967E-03BEBD1C7719 Q35043125-5F1D6454-BBF5-48B7-BE2D-23916BF8FDA0 Q35043180-A66BF275-0E2B-4C62-B4FC-FBA0DBA8C898

P2860

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.

http://www.wikidata.org/entity/Q43265482

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@en

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@nl

type

label

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@en

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@nl

prefLabel

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@en

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@nl

P1433

Q43265482-D29A7455-2A88-4F12-93C4-E7A709490211

P1476

Q43265482-98DC0E7C-1EF1-48E1-8FF9-BFF2821BA8E0

P2093

Q43265482-1C73B5DA-F830-4884-BFAE-DE90CED210EE

Q43265482-32EE8410-A30F-44B1-B61F-787D8BBC2D46

Q43265482-6A82B05F-5DC4-4EC0-B0D5-07CCB6B0AEF3

Q43265482-8F836656-BF17-415E-AFEB-6562880F2466

Q43265482-B01A7A8F-B80D-4D7A-901D-EF9D81BAA3ED

Q43265482-B80EF0BC-6710-4716-81AC-CD72B3A11F5E

Q43265482-F725E6D7-A5A5-44C6-A8D7-7B96257C5FB6

Q43265482-F8F76A70-A997-4354-BF9E-5ECFB7A6CD09

P304

Q43265482-C69C7EFA-D686-4942-BDCD-C809168879F6

P31

Q43265482-F97E95AE-3A88-4DA2-A628-D4BF4AAB0677

P356

Q43265482-753611C8-3A77-42C1-909E-B40651FB401A

P407

Q43265482-7B01A006-B0C7-4FA1-A84B-3F4840C4ACDE

P433

Q43265482-F0CA168B-667B-4D49-B212-62D70F3BB1AC

P478

Q43265482-94F0965B-947E-4CB6-A5D8-23791D5254C6

P50

Q43265482-2DD48284-937F-4157-9FAC-878D73313645

Q43265482-7C98CE24-1693-4D6C-A57F-C0D3B13333C3

Q43265482-D3ACD970-A068-4066-979F-BDD1E1600B9E

P577

Q43265482-23C8E3A3-EFE4-449A-979E-6AC57F749AA3

P5875

Q43265482-CB695303-29AB-483F-BB8B-083830184DC9

P698

Q43265482-0715EF93-9962-49AB-996B-591CFB1CC288

P356

J.BIOPSYCH.2009.07.036

P1433

Biological Psychiatry

P1476

Efficacy of d-cycloserine for ...... or therapy for panic disorder.

@en

P2093

David F Tolin

http://www.w3.org/2001/XMLSchema#string

Godfrey D Pearlson

http://www.w3.org/2001/XMLSchema#string

John H Krystal

http://www.w3.org/2001/XMLSchema#string

Katherine Eisenmenger

http://www.w3.org/2001/XMLSchema#string

Mark H Pollack

http://www.w3.org/2001/XMLSchema#string

Naomi M Simon

http://www.w3.org/2001/XMLSchema#string

Shawnee Basden

http://www.w3.org/2001/XMLSchema#string

Suzanne A Meunier

http://www.w3.org/2001/XMLSchema#string

P304

365-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOPSYCH.2009.07.036

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Godfrey D. Pearlson

Stefan G. Hofmann

Michael W. Otto

P577

2009-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26878642

http://www.w3.org/2001/XMLSchema#string

P698

19811776

http://www.w3.org/2001/XMLSchema#string